Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
We forecast the prevalence of preclinical and clinical Alzheimer's disease (AD) and evaluated potential impacts of primary and secondary preventions in the United States.
We used a multistate model incorporating biomarkers for preclinical AD with US population projections.
Approximately 6.08 million Americans had either clinical AD or mild cognitive impairment due to AD in 2017 and that will grow to 15.0 million by 2060. In 2017, 46.7 million Americans had preclinical AD (amyloidosis, neurodegeneration, or both), although many may not progress to clinical disease during their lifetimes. Primary and secondary preventions have differential impact on future disease burden.
Because large numbers of persons are living with preclinical AD, our results underscore the need for secondary preventions for persons with existing AD brain pathology who are likely to develop clinical disease during their lifetimes as well as primary preventions for persons without preclinical disease.
Forecasted preclinical and clinical Alzheimer's disease (AD) in the United States using multistate model.
Most persons living with AD brain pathology do not have clinical disease.
Fifteen million persons in the United States will be living with mild cognitive impairment due to AD or clinical AD by 2060.
Primary and secondary preventions have differential impacts on future disease burden.
|alzjjalz201710009-sup-0001.docxapplication/docx, 157.4 KB||Supplementary Material|
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
- , , , , , , et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7: 2011; 280–292
- , , , , , , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7: 2011; 270–279
- , , , , , , et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7: 2011; 263–269
- , , , , , , et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9: 2010; 119–128
- , , , , , , et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12: 2013; 357–367
- . Defining and labeling disease modifying treatments for Alzheimer's disease. Alzheimer's Dement. 5: 2009; 406–418
- . Barriers for prevention and prodromal AD trials. J Prev Alzheimer's Dis. 3: 2016; 66–67
-  National Academies of Science, Engineering and Medicine Preventing cognitive decline and dementia: a way forward. 2017; The National Academies Press: Washington, DC
- , , . Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. Expert Rev Neurother. 17: 2017; 7–16
- , , , , , , et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's Dement. 7: 2011; 61–73
- , , , , , , et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 29: 2007 29; 125–132
- , , . Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 88: 1998; 1337–1342
- , , , , . Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 60: 2003; 1119–1122
- , , , . Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement. 3: 2007; 186–191
- , . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297: 2002; 353–356
- , , , , , , et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 73: 2013; 472–480
- . PART and SNAP. Acta Neuropathol. 128: 2014; 773–776
- , , , , , , et al. Suspected non-Alzheimer disease pathophysiology - concept and controversy. Nat Rev Neurol. 12: 2016; 117–124
- , , , , , , et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 15: 2016; 56–64
- , , , , , , et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 30: 2008; 58–69
- , , , , , , et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 138: 2015; 1327–1338
- , , , , , , et al. Measuring Alzheimer's disease progression with transition probabilities Estimates from CERAD. Neurology. 57: 2001; 957–964
- , , , , , , et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. J Am Med Assoc. 277: 1997; 806–812
- , , . Modeling the effect of Alzheimer's disease on mortality. Int J Biostat. 3: 2007; 13–28
- , , , , , , et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 140: 2004; 501–509
- , , , . Survival following a diagnosis of Alzheimer disease. Arch Neurol. 59: 2002; 1764–1767
- Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at: www.mortality.org. Accessed December 9, 2015.
-  U.S. Census Bureau, Population Projections. National Population Projection Datasets. 2014, Available at: https://www.census.gov/programs-surveys/popproj.html. Accessed September 25, 2017.
- , , , , , , et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 138: 2015; 3747–3759